A systemic inflammatory reaction is a common feature of both sarcoidosis and atherosclerosis. Endothelial-cell specific molecule 1 (endocan) is a marker of vascular pathology which also shows a correlation with inflammation, endothelial dysfunction, and atherosclerosis. The objective of this study was to evaluate the vascular involvement in sarcoidosis using serum endocan levels and brachial artery flow–mediated dilation (FMD), a marker of endothelial dysfunction. We included 53 patients with sarcoidosis without conventional cardiovascular risk factors and 40 healthy controls. Endothelial function was assessed using FMD. Endocan concentrations were measured using a commercially available enzyme-linked immunoassay. Patients with sarcoidosis had significantly higher endocan levels (306 [68] ng/mL vs 269 [73] ng/mL; P = .039) and lower FMD (2.7% [2.3%-3.2%] vs 8% [5%-13%]; P < .001) compared with the healthy group. A negative correlation was found between endocan levels and FMD in the sarcoidosis group (r = −.325, P < .007). We conclude that sarcoidosis is associated with high levels of endocan and lower FMD values, which may indicate endothelial dysfunction and an early stage of atherosclerosis.
SiasosGTousoulisDGialafosE. The association between glaucoma, vascular function and inflammatory process. Int J Cardiol. 2011;146(1):113–5.
3.
ArdicIYarliogluesMDogduO. Assessment of aortic elastic properties in patients with sarcoidosis. Blood Press. 2012;21(5):286–92.
4.
YildizM. Arterial distensibility in chronic inflammatory rheumatic disorders. Open Cardiovasc Med J. 2010;4:83–8.
5.
HanMKMcLaughlinVVCrinerGJMartinezFJ. Pulmonary diseases and the heart. Circulation. 2007;116(25):2992–3005.
6.
SiasosGParaskevopoulosTGialafosE. Vascular function and ocular involvement in sarcoidosis. Microvasc Res. 2015;100:54–8.
7.
IvaniševicJKotur-StevuljevicJStefanovicA. Dyslipidemia and oxidative stress in sarcoidosis patients. Clin Biochem. 2012;45(9):677–82.
8.
KaperonisEALiapisCDKakisisJDDimitroulisDPapavassiliouVG. Inflammation and atherosclerosis. Eur J Vasc Endovasc Surg. 2006;31(4):386–93.
9.
LaneHASmithJCDaviesJS. Noninvasive assessment of preclinical atherosclerosis. Vasc Health Risk Manag. 2006;2(1):19–30.
10.
TuletaIPingelSBienerL. Atherosclerotic vessel changes in sarcoidosis. Adv Exp Med Biol. 2016;910:23–30.
11.
SamanciNSPoturogluSSamanciC. Evaluation of carotid intima-media thickness with vascular endothelial growth factor and malondialdehyde levels in patients with sarcoidosis. Diagn Interv Imaging. 2017;98(7-8):557–61.
12.
SarrazinSAdamELyonM. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006;1765(1):25–37.
13.
BechardDScherpereelAHammadH. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol. 2001;167(6):3099–106.
14.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277–304.
15.
HunninghakeGWCostabelUAndoM. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. 1999;16(2):149–73.
16.
CorrettiMCAndersonTJBenjaminEJ. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediatedvasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39(2):257–65.
17.
KuvinJTPatelARSlineyKA. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol. 2001;38(7):1843–9.
18.
HabersbergerJManinsVTaylorAJ. Cardiac sarcoidosis. Intern Med J. 2008;38(4):270–7.
19.
MenonPKocherONAirdWC. Endothelial cell specific molecule-1 (ESM-1), a novel secreted proteoglycan stimulates vascular smooth muscle cell proliferation and migration. Circulation. 2011;124:A15455.
20.
Von FeldtJM. Premature atherosclerotic cardiovascular disease and systemic lupus erythematosus from bedside to bench. Bull NYU Hosp Jt Dis. 2008;66(3):184–7.
21.
Maksimowicz-McKinnonKHoffmanGS. Large-vessel vasculitis. Semin Respir Crit Care Med. 2004;25(5):569–79.
22.
TsukadaNYanagisawaNMochizukiI. Endothelial cell damage in sarcoidosis and neurosarcoidosis: autoantibodies to endothelial cells. Eur Neurol. 1995;35(2):108–12.
23.
SfikakisPPPapamichaelCStamatelopoulosKS. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56(6):1985–93.
24.
WatanabeTTakemuraMSatoM. Clinical significance of brachial flow-mediated dilation in patients with rheumatoid arthritis. Int J Rheum Dis. 2014;17(1):26–33.
25.
AvgerinouGTousoulisDSiasosG. Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis. Int J Cardiol. 2011;151(3):382–3.
26.
KulSKutluGAGuvencTS. Coronary flow reserve is reduced in sarcoidosis. Atherosclerosis. 2017;264:115–21.
27.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTIyisoyA. Endocan: a novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243:339–43.
28.
BlankenbergSBarbauxSTiretL. Adhesion molecules and atherosclerosis. Atherosclerosis. 2003;170(2):191–203.
29.
BaltaIBaltaSDemirkolS. Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. 2013;169(5):1066–70.
30.
YilmazMISiriopolDSaglamM. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014; 86(6):1213–20.
31.
LeeWKuSKKimSWBaeJS. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014;229(5):620–30.
32.
ScherpereelADepontieuFGrigoriuB. Endocan, a new endothelial marker in human sepsis. Crit Care Med. 2006;34(2):532–7.
33.
BaltaSMikhailidisDPDemirkolSCelikTOzturkCIyisoyA. Endocan and atherosclerosis. Angiology. 2015;66(5):490.
34.
KoseMEmetSAkpinarTS. Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology. 2014;66(8):727–31.
35.
BaltaSMikhailidisDPDemirkolS. Endocan—a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology. 2014;65(9):773–7.
36.
KundiHGokMKiziltuncE. The relationship between serum endocan levels with the presence of slow coronary flow: a cross-sectional study. Clin Appl Thromb Hemost. 2017;23(5):472–7.
37.
BaltaIBaltaSKoryurekOM. Serum endocan levels as a marker of disease activity in patients with Behcet disease. J Am Acad Dermatol. 2014;70(2):291–6.
38.
IcliACureECureMC. Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67(8):749–55.
39.
BaltaSDemirkolSOzturkCYildirimAODemirMCelikT. The relation between endocan levels and subclinic atherosclerosis. Clin Appl Thromb Hemost. 2016;22(5):495–6.
40.
GuzelADuranLKoksalN. Evaluation of serum endothelial cell specific molecule-1 (endocan) levels as a biomarker in patients with pulmonary thromboembolism. Blood Coagul Fibrinolys. 2014;25(3):272–6.
41.
KaoSJChuangCYTangCH. Plasma endothelial cellspecificmolecule-1 (ESM-1) in management of community acquired pneumonia. Clin Chem Lab Med. 2014;52(3):445–51.
42.
CreagerMACookeJPMendelsohnME. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990;86(1):228–34.
43.
TreasureCBKleinJLWeintraubWS. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332(8):481–7.
44.
CelikTBaltaSKaramanM. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015;24(1):55–60.
45.
LassallePMoletSJaninA. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271(34):20458–64.
